department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Temsirolimus · pharmadog

pharmadog
drugs
Temsirolimus

drug

patient view →

temsirolimus

Marketedupdated 2mo ago

by Accord Healthcare Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Temsirolimus

generic

temsirolimus

indication

Metastatic Renal Cell Carcinoma

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 20, 2026

13 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Nov 10, 2032patentUS 8791097*PED
May 10, 2032method-of-use (U-1550)US 8791097
Jul 20, 2026patentUS 8026276*PED13d
Jan 20, 2026formulationUS 8026276

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 3m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Trials studying temsirolimus

phase2TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancerrecruitingn=4,200
phase2A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumoursactive not recruitingn=137
phase2Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)recruitingn=720
phase1A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)active not recruitingn=140
N/ATorisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancerwithdrawn
phase3Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Kneerecruitingn=250
—Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)completedn=1,050
—Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]completedn=1,520

more trials →